Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
$9.38
+2.6%		$8.49
$7.00
▼
$14.87
$753.60M0.35355,519 shs29,489 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.41
+3.5%		$3.42
$1.90
▼
$8.21
$744.13M2.124.88 million shs935,260 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.42
+0.2%		$2.33
$1.52
▼
$3.19
$194.58M0.02928,253 shs43,251 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.92
+10.6%		$10.93
$5.45
▼
$16.19
$585.51M0.941.45 million shs610,177 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
+0.66%+1.11%+3.63%+9.20%+913,999,900.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+0.30%-4.64%+1.54%-10.84%+55.19%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+1.26%+5.24%+1.69%+12.62%+45.18%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-24.81%-28.86%-17.16%+27.73%-10.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
$9.38
+2.6%		$8.49
$7.00
▼
$14.87
$753.60M0.35355,519 shs29,489 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$3.41
+3.5%		$3.42
$1.90
▼
$8.21
$744.13M2.124.88 million shs935,260 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.42
+0.2%		$2.33
$1.52
▼
$3.19
$194.58M0.02928,253 shs43,251 shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$8.92
+10.6%		$10.93
$5.45
▼
$16.19
$585.51M0.941.45 million shs610,177 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
+0.66%+1.11%+3.63%+9.20%+913,999,900.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+0.30%-4.64%+1.54%-10.84%+55.19%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+1.26%+5.24%+1.69%+12.62%+45.18%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-24.81%-28.86%-17.16%+27.73%-10.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
2.75
Moderate Buy$24.40160.27% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.83
Moderate Buy$11.90249.49% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$12.00396.89% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.62
Moderate Buy$23.45163.09% Upside

Current Analyst Ratings Breakdown

Latest PLX, CTMX, RGNX, and BBOT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/25/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$32.00 ➝ $29.00
8/19/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/14/2026
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$27.00 ➝ $25.00
8/13/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$12.00 ➝ $11.00
8/12/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/10/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$15.00 ➝ $14.00
8/10/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$26.00 ➝ $23.00
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$18.00
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Hold
8/7/2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$12.00
7/21/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
N/AN/AN/AN/A$5.14 per shareN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M9.74N/AN/A$0.58 per share5.87
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$80.62M2.41$0.14 per share17.80$0.47 per share5.14
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$170.44M3.45N/AN/A$2.03 per share4.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
-$134.04M-$2.76N/AN/AN/AN/A-46.90%-42.17%N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.50N/AN/AN/A-435.21%-38.46%-30.33%11/5/2026 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.23N/A7.79N/A-21.03%-30.89%-11.74%N/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$193.88M-$3.79N/AN/AN/A-112.58%-220.07%-46.04%11/5/2026 (Estimated)

Latest PLX, CTMX, RGNX, and BBOT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
N/A-$705.20N/A-$705.20N/AN/A
8/6/2026Q2 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.0771-$0.09-$0.0129-$0.09$12.39 million$1.42 million
8/6/2026Q2 2026
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.0787$0.43+$0.3513$0.43$97.63 million$108.02 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
N/A
4.69
4.69
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
9.36
9.36
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.86
2.86

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
54.89%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%

Insider Ownership

CompanyInsider Ownership
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
24.40%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.80%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.70%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
14.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Oncology Therapeutics, Inc stock logo
BBOT
BridgeBio Oncology Therapeutics
N/A80.17 million60.61 millionN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
170217.90 million209.62 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20080.57 million69.00 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37066.01 million56.63 millionOptionable

Recent News About These Companies

REGENXBIO (NASDAQ:RGNX) Price Target Cut to $29.00 by Analysts at Robert W. Baird
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-regenxbio-nasdaq-rgnx-price-target-cut-to-2900-by-analysts-at-robert-w-baird-2026-08-25/
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/regenxbio-strengthens-board-of-directors-with-appointment-of-greg-ciongoli-302858908.html
Regenxbio (RGNX) Stock Plummets 25% as FDA Halts Gene Therapy Trial
August 25 at 5:16 AM  |  blockonomi.comhttps://blockonomi.com/regenxbio-rgnx-stock-plummets-25-as-fda-halts-gene-therapy-trial/
RGNX Stock Faces Biggest Drop in Over Three Months – But BofA Urges Buyers to Seize the Opportunity Despite FDA Setback on Gene Therapy
August 24 at 10:40 PM  |  profitconfidential.comP
RGNX stock on track for worst day in over three months — BofA says buy despite ‘disappointing’ FDA hold on gene therapy
August 24 at 10:40 PM  |  msn.comhttps://www.msn.com/en-us/health/general/rgnx-stock-on-track-for-worst-day-in-over-three-months-bofa-says-buy-despite-disappointing-fda-hold-on-gene-therapy/ar-AA2aPGNK
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold
August 24 at 2:18 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3350064/0/en/rgnx-investor-notice-johnson-fistel-investigates-regenxbio-inc-following-clinical-hold.html
Regenxbio Won't Resubmit US FDA Biologics License Application for Hunter Syndrome Therapy; Shares Down Pre-Bell
August 24 at 12:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/regenxbio-won-apos-t-resubmit-113547297.html
REGENXBIO shares plunge after FDA places clinical hold on RGX-121
August 24 at 12:39 PM  |  msn.comhttps://www.msn.com/en-us/science/biology/regenxbio-shares-plunge-after-fda-places-clinical-hold-on-rgx-121/ar-AA2aOr7k
Regenxbio sinks as FDA puts RGX-121 gene therapy on clinical hold
August 24 at 12:39 PM  |  msn.comhttps://www.msn.com/en-us/money/other/regenxbio-sinks-as-fda-puts-rgx-121-gene-therapy-on-clinical-hold/ar-AA2aOxF7
REGENXBIO (NASDAQ:RGNX) Shares Gap Down - Should You Sell?
August 24 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-shares-gap-down-should-you-sell-2026-08-24/
Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial
August 24 at 8:39 AM  |  barrons.comhttps://www.barrons.com/articles/regenxbio-stock-gene-therapy-trial-f2a9b838
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
August 24 at 7:25 AM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/fda-places-clinical-hold-regenxbios-gene-therapy-hunter-syndrome-2026-08-24/
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
August 24 at 7:05 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/regenxbio-announces-regulatory-update-on-rgx-121-for-mps-ii-302858018.html
REGENXBIO (NASDAQ:RGNX) Trading Down 3.9% - Should You Sell?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-trading-down-39-should-you-sell-2026-08-21/
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-walleye-capital-llc-invests-244-million-in-regenxbio-inc-rgnx-2026-08-15/
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/regenxbio-nasdaqrgnx-rating-increased-to-hold-at-zacks-research-2026-08-14/
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-has-203-million-position-in-regenxbio-inc-rgnx-2026-08-14/
Research Analysts Set Expectations for REGENXBIO Q3 Earnings
August 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959269
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
August 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RGNX/pressreleases/3734740/bank-of-america-securities-reaffirms-their-buy-rating-on-regenxbio-rgnx/
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-pessimistic-view-of-regenxbio-q3-earnings-2026-08-12/
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934891-regenxbios-multi-catalyst-setup-is-hard-to-ignore-rating-upgrade

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Oncology Therapeutics stock logo

BridgeBio Oncology Therapeutics NASDAQ:BBOT

$9.38 +0.24 (+2.57%)
As of 11:23 AM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Throughout this prospectus, we will refer to this as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business or industry, we intend to focus on healthcare or healthcare related industries, which can benefit from the expertise and capabilities of our management team in order to create long-term shareholder value. Our sponsor is an affiliate of Cormorant, a leading life sciences focused investment firm with over $2 billion in assets under management as of December 31, 2022. Our Chairperson and Chief Executive Officer, Bihua Chen, founded Cormorant and is the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$3.40 +0.12 (+3.50%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$2.42 +0.01 (+0.21%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$8.91 +0.86 (+10.61%)
As of 11:24 AM Eastern
This is a fair market value price provided by Massive. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas